Answers are grounded in this paper and cite their sources.
These results reveal that PF-03084014 enhances docetaxel-mediated tumor response and provides a rationale to explore GSIs as adjunct therapy in conjunction with docetaxel for men with CRPC.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: